Press Releases

All Releases
View Summary Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
Jan 26, 2015
PDF 27.4 KB
View Summary Synageva BioPharma Announces Pricing of Public Offering of Common Stock
Jan 6, 2015
PDF 24.1 KB
View Summary Synageva BioPharma Announces A 2.5 Million Share Proposed Public Offering Of Its Common Stock
Jan 5, 2015
PDF 24.1 KB
View Summary Synageva BioPharma Announces New Pipeline Programs And Other Company Progress
Jan 5, 2015
PDF 30.9 KB
View Summary Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA
Dec 23, 2014
PDF 24.2 KB
View Summary Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST
Dec 17, 2014
PDF 21.1 KB
View Summary Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB
Dec 15, 2014
PDF 25.0 KB
View Summary Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa And Submits Marketing Authorization Application To European Medicines Agency
Dec 2, 2014
PDF 26.5 KB
View Summary Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting
Nov 10, 2014
PDF 29.9 KB
View Summary Synageva BioPharma Reports Third Quarter 2014 Financial Results
Oct 30, 2014
PDF 29.8 KB
View Summary Synageva BioPharma to Present at the Nomura Biotechnology Conference
Oct 29, 2014
PDF 19.5 KB
View Summary Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting
Oct 23, 2014
PDF 27.7 KB
View Summary Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa
Oct 21, 2014
PDF 24.2 KB
View Summary Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral Presentation During The Late-Breaking Session At The Liver Meeting®
Oct 8, 2014
PDF 24.1 KB
View Summary Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer
Sep 22, 2014
PDF 23.3 KB
View Summary Synageva BioPharma To Present At The Morgan Stanley Global Healthcare Conference
Sep 2, 2014
PDF 19.8 KB
View Summary Synageva BioPharma™ To Present At The Baird 2014 Healthcare Conference
Aug 26, 2014
PDF 21.4 KB
View Summary Synageva BioPharma™ To Present At Upcoming Investor Conferences
Aug 4, 2014
PDF 21.5 KB
View Summary Synageva BioPharma™ Reports Second Quarter 2014 Financial Results
Jul 30, 2014
PDF 31.1 KB
View Summary Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency
Jun 30, 2014
PDF 26.7 KB
Showing 1-20 of 125 Page: 1 2 3 4 5 ... 7  Next 20